清热八味胶囊联合布地奈德治疗慢性阻塞性肺疾病急性加重期的临床效果。

Clinical effect of qingre bawei capsules combined with budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease.

机构信息

Baoding No.1 Central Hospital, China.

出版信息

J Pak Med Assoc. 2024 Aug;74(8):1470-1473. doi: 10.47391/JPMA.10244.

DOI:10.47391/JPMA.10244

PMID:39160715

Abstract

OBJECTIVE

To assess the clinical effect of Qingre Bawei capsules combined with budesonide in the treatment of acute exacerbation of chronic obstructive pulmonary disease.

METHODS

The retrospective study was conducted at the Baoding No.1 Central Hospital, China, and comprised data of patients with acute exacerbation of COPD admitted between June 1, 2020, and June 30, 2022. The patients were divided into two groups based on treatment methods. The group A had been treated with Qingre Bawei capsules in combination with budesonide, while the group B had been treated with budesonide alone. Both the groups had been treated for 2 consecutive weeks. The changes in blood gas indicators, inflammation indicators, and lung function indicators were compared between two groups of patients before and 24 hours after treatment. The time for clinical symptom disappearance and adverse reactions between the two groups of patients was also noted.

RESULTS

Of the 120 patients, 60(50%) were in group A; 41(68.3%) males and 19(31.7%) females, with mean age 65.28±4.36 years (range: 47-78 years) and mean course of disease 31.22±4.75 hours (range: 6-65 hours). 60(50%) patients were in group B; 43(71.7%) males and 17(28.3%) females with mean age 65.31±4.31 years (range: 48-78 years) and mean course of disease 31.29±4.71 hours (range: 8-68 hours). The disappearance time of clinical symptoms in group A was better than group B (p<0.05). The levels of blood gas indicators, inflammation indicators, and lung function indicators in both groups significantly improved (p<0.05), but the degree of improvement in group A was better than group B (p<0.05); The total effective rate of group A was better than group B (p<0.05). None of the patients in either group experienced any significant adverse reaction.

CONCLUSIONS

Qingre Bawei capsules combined with budesonide had a significantly better therapeutic effect on cases of acute exacerbation of chronic obstructive pulmonary disease compared to budesonide alone.

摘要

目的

评估清热八味胶囊联合布地奈德治疗慢性阻塞性肺疾病急性加重的临床疗效。

方法

本回顾性研究在中国保定市第一中心医院开展，纳入 2020 年 6 月 1 日至 2022 年 6 月 30 日收治的急性加重期慢性阻塞性肺疾病患者，根据治疗方法分为两组。A 组采用清热八味胶囊联合布地奈德治疗，B 组采用布地奈德单独治疗。两组均连续治疗 2 周。比较两组患者治疗前后 24 h 血气指标、炎症指标和肺功能指标的变化，记录两组患者临床症状消失时间和不良反应发生情况。

结果

120 例患者中，A 组 60 例（50.0%），男 41 例（68.3%），女 19 例（31.7%），年龄 65.28±4.36 岁（范围：47-78 岁），病程 31.22±4.75 h（范围：6-65 h）；B 组 60 例（50.0%），男 43 例（71.7%），女 17 例（28.3%），年龄 65.31±4.31 岁（范围：48-78 岁），病程 31.29±4.71 h（范围：8-68 h）。A 组临床症状消失时间优于 B 组（p<0.05）。两组血气指标、炎症指标和肺功能指标水平均明显改善（p<0.05），但 A 组改善程度优于 B 组（p<0.05）；A 组总有效率优于 B 组（p<0.05）。两组患者均未出现明显不良反应。